DK1285002T3 - Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet - Google Patents

Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet

Info

Publication number
DK1285002T3
DK1285002T3 DK01948240T DK01948240T DK1285002T3 DK 1285002 T3 DK1285002 T3 DK 1285002T3 DK 01948240 T DK01948240 T DK 01948240T DK 01948240 T DK01948240 T DK 01948240T DK 1285002 T3 DK1285002 T3 DK 1285002T3
Authority
DK
Denmark
Prior art keywords
regulation
methods
present
zmax1
lipid
Prior art date
Application number
DK01948240T
Other languages
Danish (da)
English (en)
Inventor
John P Carulli
Randall D Little
Robert R Recker
Mark L Johnson
Original Assignee
Oscient Pharmaceuticals Corp
Univ Creighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscient Pharmaceuticals Corp, Univ Creighton filed Critical Oscient Pharmaceuticals Corp
Application granted granted Critical
Publication of DK1285002T3 publication Critical patent/DK1285002T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
DK01948240T 2000-05-26 2001-05-25 Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet DK1285002T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57890000A 2000-05-26 2000-05-26
PCT/US2001/016946 WO2001092891A2 (en) 2000-05-26 2001-05-25 Regulating lipid levels via the zmax1 or hbm gene

Publications (1)

Publication Number Publication Date
DK1285002T3 true DK1285002T3 (da) 2007-10-29

Family

ID=24314783

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01948240T DK1285002T3 (da) 2000-05-26 2001-05-25 Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet

Country Status (15)

Country Link
EP (1) EP1285002B1 (de)
JP (1) JP2004523724A (de)
CN (1) CN100469792C (de)
AT (1) ATE367401T1 (de)
AU (2) AU6971201A (de)
BR (1) BR0111057A (de)
CA (1) CA2410253C (de)
DE (1) DE60129433T2 (de)
DK (1) DK1285002T3 (de)
ES (1) ES2290155T3 (de)
IL (2) IL152654A0 (de)
MX (1) MXPA02011588A (de)
NZ (1) NZ522600A (de)
WO (1) WO2001092891A2 (de)
ZA (1) ZA200208977B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
WO2002092000A2 (en) 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
JP2005512508A (ja) * 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
GB201516972D0 (en) * 2015-09-25 2015-11-11 Epiontis Gmbh LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification
CN111334589B (zh) * 2020-05-08 2023-03-17 武汉市农业科学院 一种与连城白鸭白羽羽色相关的分子标记及连城白鸭杂交白羽后代的选育方法
CN115376612B (zh) * 2022-09-13 2023-10-13 郑州思昆生物工程有限公司 一种数据评测方法、装置、电子设备及存储介质

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837542T2 (de) * 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
WO2002092000A2 (en) * 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels

Also Published As

Publication number Publication date
DE60129433D1 (de) 2007-08-30
CN1444601A (zh) 2003-09-24
DE60129433T2 (de) 2008-04-17
AU6971201A (en) 2001-12-11
WO2001092891A3 (en) 2002-07-25
CA2410253A1 (en) 2001-12-06
NZ522600A (en) 2004-09-24
MXPA02011588A (es) 2004-05-17
ATE367401T1 (de) 2007-08-15
EP1285002A2 (de) 2003-02-26
WO2001092891A2 (en) 2001-12-06
CN100469792C (zh) 2009-03-18
ES2290155T3 (es) 2008-02-16
CA2410253C (en) 2010-06-15
AU2007200880A1 (en) 2007-03-22
IL152654A (en) 2010-05-31
EP1285002B1 (de) 2007-07-18
IL152654A0 (en) 2003-06-24
ZA200208977B (en) 2003-11-05
BR0111057A (pt) 2003-04-15
JP2004523724A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
DK1285002T3 (da) Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet
Pfeifer Formation and processing of UV photoproducts: effects of DNA sequence and chromatin environment
Wiederholt et al. Repair of DNA Containing Fapy⊙ dG and Its β-C-Nucleoside Analogue by Formamidopyrimidine DNA Glycosylase and MutY
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
Allmang et al. The SBP2 and 15.5 kD/Snu13p proteins share the same RNA binding domain: identification of SBP2 amino acids important to SECIS RNA binding
McKibbin et al. Repair of hydantoin lesions and their amine adducts in DNA by base and nucleotide excision repair
Goodman et al. In vitro selection of integration host factor binding sites
Boström et al. Apolipoprotein B48 RNA editing in chimeric apolipoprotein EB mRNA
Sémonin et al. Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva
Lee et al. RNA annealing activity is intrinsically associated with U2AF
DK1200117T3 (da) Behandling med lipoprotein-lipase (LPL) variant
Smith Apolipoprotein B mRNA editing: the sequence to the event
Slavov et al. Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish
PT1406898E (pt) Compostos de piperazina substituida e sua utilizacao como inibidores de oxidacao de acidos gordos
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
Durliat et al. Conserved protein motifs and structural organization of a fish gene homologous to mammalian apolipoprotein E
Baljinnyam et al. Chemical and enzymatic modifications of 5-methylcytosine at the intersection of DNA damage, repair, and epigenetic reprogramming
MXPA02009791A (es) El gen de alta masa osea de 11q13.3.
Mekhovich et al. Rate of Incision of N-Acetyl-2-aminofluorene and N-2-Aminofluorene Adducts by UvrABC Nuclease Is Adduct-and Sequence-Specific: Comparison of the Rates of UvrABC Nuclease Incision and Protein− DNA Complex Formation
EE200100040A (et) Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks
Kroeger et al. Effects of the C4 ‘-oxidized abasic site on replication in Escherichia coli. An unusually large deletion is induced by a small lesion
DK1268775T3 (da) Höjt knoglemassegen af 11Q13.3
EP1197550A3 (de) Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
Granger et al. Human hnRNPA1 reorganizes telomere-bound replication protein A
Has et al. Novel keratin 14 mutations in patients with severe recessive epidermolysis bullosa simplex